JPRN-UMIN000010970
Recruiting
未知
Elucidation of renal function protection with human atrial natriuretic peptide (hANP) - Elucidation of renal function protection with hANP
Department of anesthesiology, Faculty of medicine,Kagawa university0 sites30 target enrollmentJune 14, 2013
Conditionsischemic heart disease
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- ischemic heart disease
- Sponsor
- Department of anesthesiology, Faculty of medicine,Kagawa university
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •preoperative renal disfunction , not heart failure
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Examination of the effect of renal protection of aliskiren in chronic renal failure patient with hypertension (preservation period)Chronic renal failure patient with hypertension under going rennin-angiotensin treatment (ARB/ACE-inhibitor) (preservation period)JPRN-UMIN000002478Kure Kyousai Hospital200
Not yet recruiting
Not Applicable
Study of renal function renal protective effect of cooling method in laparoscopic partial nephrectomyRenal cell cacinomaJPRN-UMIN000013867Kansai Medical University30
Completed
Not Applicable
The investigation of the renal protective effect of Carperitide(hANP:human atrial natriuretic peptide) during adult living donor renal transplantation, a single center experience.living donor renal transplantationJPRN-UMIN000014279Toho University School of Medicine, Department of Anesthesiology30
Completed
Not Applicable
An observational study of renal protection by intravenous amino acid therapy in abdominal aortic aneurysm surgeryabdominal aortic aneurysmJPRN-UMIN000038527ational Cerebral and Cardiovascular Center2,000
Active, not recruiting
Phase 1
Evaluation of the impact of renal function on the pharmacokinetics of hydroxyurea (Siklos®) in patients with sickle cell disease with normal renal function, with hyperfiltration, or with renal failure. DARH studySiklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in adults, adolescents and children older than 2 years suffering from symptomatic sickle cell syndrome.MedDRA version: 17.1Level: LLTClassification code 10040643Term: Sickle cell crisisSystem Organ Class: 100000004851Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2014-005033-31-FRAddmedica S.A.S